Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:ZLAB 24 December 2025 - 26 December 2025

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab shares were indicated around $18.58 premarket Friday, valuing the company near $2.1 billion. China approved COBENFY for schizophrenia on December 23, adding to recent company catalysts. U.S. markets reopen for a full session after the Christmas holiday, with thin liquidity and wider spreads expected. ZLAB’s 52-week range spans $16.82 to $44.34, with momentum indicators near oversold levels.
26 December 2025
···
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

China’s NMPA approved Zai Lab’s COBENFY for adult schizophrenia on Dec. 23, triggering a surge in Zai Lab shares. The U.S. ADR traded around $18.54 intraday, while Hong Kong shares closed at HK$14.48, up 6.24%. COBENFY is the first M1/M4 muscarinic receptor therapy for schizophrenia approved in China. Zai Lab holds exclusive commercialization rights in Greater China.
24 December 2025
···
Go toTop